CSIMarket
 


Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 
 

CYTK's Income from Cont. Operations Growth by Quarter and Year

Cytokinetics Incorporated's Income from Cont. Operations results by quarter and year




CYTK Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -137.38 -30.57 -43.93
III Quarter September -129.42 -142.31 -76.09 -3.18
II Quarter June -128.64 -19.82 -61.55 -40.78
I Quarter March -131.29 -89.45 -47.10 -39.41
FY   -389.35 -388.96 -215.31 -127.30



CYTK Income from Cont. Operations third quarter 2023 Y/Y Growth Comment
Cytokinetics Incorporated in the third quarter 2023 recorded loss from continued operations of $ -129.42 millions.

According to the results reported in the third quarter 2023, Cytokinetics Incorporated achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Cytokinetics Incorporated' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2023.




CYTK Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Cytokinetics Incorporated's third quarter 2023 Income from Cont. Operations $ -129.42 millions CYTK's Income Statement
Cytokinetics Incorporated's third quarter 2022 Income from Cont. Operations $ -142.31 millions Quarterly CYTK's Income Statement
New: More CYTK's historic Income from Cont. Operations Growth >>


CYTK Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Cytokinetics Incorporated's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYTK's III. Quarter Q/Q Income from Cont. Operations Comment
Recent results of -129.42 millions by Cytokinetics Incorporated come out even more unfavourable if you take a look at -128.64 millions loss from continued operations in the second quarter.

Within Major Pharmaceutical Preparations industry Cytokinetics Incorporated achieved highest sequential Income from Cont. Operations growth. While Cytokinetics Incorporated's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYTK's III. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -129.42 millions by Cytokinetics Incorporated come out even worse compare to the -128.64 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Cytokinetics Incorporated achieved highest sequential Income from Cont. Operations growth. While Cytokinetics Incorporated's Income from Cont. Operations growth quarter on quarter, overall rank is .


Cytokinetics Incorporated's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -526.73 $ -539.62 $ -430.80 $ -388.96 $ -282.15
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Cytokinetics Incorporated' has realized cumulative trailing twelve months loss from continued operations of $ -527 millions in the Sep 30 2023 period.

Cytokinetics Incorporated achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Cytokinetics Incorporated' has realized cumulative trailing twelve months loss from continued operations of $ -527 millions in the Sep 30 2023 period.

Cytokinetics Incorporated achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
CYTK's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for CYTK's Competitors
Income from Cont. Operations Growth for Cytokinetics Incorporated's Suppliers
Income from Cont. Operations Growth for CYTK's Customers

You may also want to know
CYTK's Annual Growth Rates CYTK's Profitability Ratios CYTK's Asset Turnover Ratio CYTK's Dividend Growth
CYTK's Roe CYTK's Valuation Ratios CYTK's Financial Strength Ratios CYTK's Dividend Payout Ratio
CYTK's Roa CYTK's Inventory Turnover Ratio CYTK's Growth Rates CYTK's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2023
Shockwave Medical Inc -0.05%$ -0.049 millions
Xeris Biopharma Holdings Inc -0.29%$ -0.295 millions
Tenet Healthcare Corp-0.75%$ -0.746 millions
U S Physical Therapy Inc-4.67%$ -4.672 millions
Universal Health Services Inc -4.98%$ -4.979 millions
National Research Corporation-5.09%$ -5.086 millions
Hca Healthcare Inc -5.13%$ -5.134 millions
Viatris Inc -6.41%$ -6.407 millions
Pacific Health Care Organization Inc -6.71%$ -6.710 millions
Mettler Toledo International Inc-8.60%$ -8.598 millions
Corcept Therapeutics Inc-9.78%$ -9.777 millions
Charles River Laboratories International inc -9.83%$ -9.826 millions
Third Harmonic Bio Inc -10.51%$ -10.506 millions
The Pennant Group Inc -10.65%$ -10.653 millions
Henry Schein Inc -11.73%$ -11.728 millions
Quest Diagnostics Inc-14.13%$ -14.130 millions
Carlisle Companies Incorporated-15.01%$ -15.008 millions
Stryker Corp-15.20%$ -15.196 millions
Zimmer Biomet Holdings Inc -16.12%$ -16.117 millions
Amgen Inc -19.27%$ -19.272 millions
Entera Bio Ltd -22.43%$ -22.432 millions
Regeneron Pharmaceuticals Inc -23.40%$ -23.402 millions
Pediatrix Medical Group Inc -25.75%$ -25.746 millions
Zynex inc -26.25%$ -26.247 millions
Evofem Biosciences Inc -26.26%$ -26.256 millions
Tenax Therapeutics Inc -32.39%$ -32.386 millions
Avantor Inc -35.09%$ -35.090 millions
Ufp Technologies Inc -40.15%$ -40.154 millions
Bio techne Corp-43.17%$ -43.173 millions
Royalty Pharma Plc-44.61%$ -44.615 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com